Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 2, 2015, Pages 129-138

  Devineni, Damayanthi ^a   Vaccaro, Nicole ^a   Polidori, David ^a   Stieltjes, Hans ^b   Wajs, Ewa ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Canagliflozin; Dose dependent; Pharma cokinetics; Pharmaco dynamics; Sodium glucose co transporter 2 inhibitor

Indexed keywords

CANAGLIFLOZIN; DRUG METABOLITE; GLUCOSE; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ADULT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; EC50; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE URINE LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROLOGIC DISEASE; NORMAL HUMAN; OPEN STUDY; PARALLEL DESIGN; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANTAGONISTS AND INHIBITORS; MIDDLE AGED;

ADULT; CANAGLIFLOZIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSIDES; HUMANS; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84961288553     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202218     Document Type: Article

References (21)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet. 2011; 378: 31-40. CrossRef PubMed
2. Simon D. [Epidemiological features of type 2 diabetes]. Rev Prat. 2010; 60: 469-473. PubMed
3. Cefalu W T, Richards RJ, Melendez-Ramirez L Y. Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects. Cleve Clin J Med. 2009; 76 (Suppl 5): S39-S47. CrossRef PubMed
4. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglyce-mia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193-203. CrossRef PubMed
5. Polidori D, Sha S, Ghosh A, Plum-Mörschel L, Heise T, Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013; 98: E867-E871. CrossRef PubMed
6. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg P. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011; 13: 669-672. CrossRef PubMed
7. Canagliflozin (Invokana") Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2013. Accessed on April 16, 2014. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/204042s000lbl.pdf.
8. Elkinson S, Scott LJ. Canagliflozin: first global approval. Drugs. 2013; 73: 979-988. CrossRef PubMed
9. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, Kawaguchi M, Canovatchel W, Meininger G. Canagliflozin compared with sita-gliptin for patients with type 2 diabetes who do not have adequate glycemic control with metfor-min plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013; 36: 2508-2515. CrossRef PubMed
10. Stenlöf K, Cefalu W T, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013; 15: 372-382. CrossRef PubMed
11. Inagaki N, Kondo K, Yoshinari T, Maruyama N, Susuta Y, Kuki H. Efficacy and safety of cana-gliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab. 2013; 15: 1136-1145. CrossRef PubMed
12. Yale J F, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013; 15: 463-473. Cross-Ref PubMed
13. Food and Drug Administration (FDA). Guidance for Industry, Bioanalytical Methods Validation. 2001. Accessed on April 24, 2014. Available at: http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf.
14. Viswanathan C, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, Shah V P, Skelly J P, Swann PG, Weiner R. Workshop/conference report-quantitative bioanalytical methods validation and implementation: best practices for chromato-graphic and ligand binding assays. AAPS J. 2007; 9: E30-E42. CrossRef
15. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek J W, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007; 53: 766-772. CrossRef PubMed
16. Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, Rusch S, Rothenberg PL. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2013; 53: 601-610. CrossRef PubMed
17. Nair S, Wilding J P. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mel-litus. J Clin Endocrinol Metab. 2010; 95: 34-42. CrossRef PubMed
18. Rave K, Nosek L, Posner J, Heise T, Roggen K, van Hoogdalem EJ. Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes-results of a hypergly-caemic glucose clamp study. Nephrol Dial Transplant. 2006; 21: 2166-2171. CrossRef PubMed
19. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W, Canagliflozin DIASG; Canagliflozin DIA 2001 Study Group. Dose-ranging effects of cana-gliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012; 35: 1232-1238. CrossRef PubMed
20. Mamidi RN, Cuyckens F, Chen J, Scheers E, Kalamaridis D, Lin R, Silva J, Sha S, Evans DC, Kelley M F, Devineni D, Johnson MD, Lim HK. Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans. Drug Metab Dispos. 2014; 42: 903-916. CrossRef PubMed
21. rd Annual meeting of the Japan Diabetes Society. Okayama, Japan; 2010.